A real-life experience of sorafenib treatment for patients with advanced hepatocellular carcinoma: a retrospective analysis at Cathay General Hospital, 2007–2015
Chi-Chun Huang,1 Hsin-Yi Chen,1 Ruei-Hsin Chang,1 Pen-An Liao,2 Heng-Hui Lien,3,4 Chih-Sheng Hung,5 Sien-Sing Yang,1,3 Jui-Ting Hu1,3 1Liver Center, Cathay General Hospital Medical Center, Taipei, Taiwan; 2Department of Radiology, Cathay General Hospital Medical Center, Taipei, Taiwan; 3School of M...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2019-01-01
|
| Series: | Drug Design, Development and Therapy |
| Subjects: | |
| Online Access: | https://www.dovepress.com/a-real-life-experience-of-sorafenib-treatment-for-patients-with-advanc-peer-reviewed-article-DDDT |
| _version_ | 1811323142169165824 |
|---|---|
| author | Huang CC Chen HY Chang RH Liao PA Lien HH Hung CS Yang SS Hu JT |
| author_facet | Huang CC Chen HY Chang RH Liao PA Lien HH Hung CS Yang SS Hu JT |
| author_sort | Huang CC |
| collection | DOAJ |
| description | Chi-Chun Huang,1 Hsin-Yi Chen,1 Ruei-Hsin Chang,1 Pen-An Liao,2 Heng-Hui Lien,3,4 Chih-Sheng Hung,5 Sien-Sing Yang,1,3 Jui-Ting Hu1,3 1Liver Center, Cathay General Hospital Medical Center, Taipei, Taiwan; 2Department of Radiology, Cathay General Hospital Medical Center, Taipei, Taiwan; 3School of Medicine, Fu-Jen Catholic University College of Medicine, Taipei, Taiwan; 4Department of Surgery, Cathay General Hospital Medical Center, Taipei, Taiwan; 5Department of Gastroenterology, Cathay General Hospital Medical Center, Taipei, Taiwan Background: Sorafenib is an oral tyrosine kinase inhibitor that is indicated for advanced hepatocellular carcinoma (HCC). The aim of the present study was to determine the clinical outcomes of HCC patients receiving sorafenib in real-life clinical setting in comparison with formal clinical trials.Methods: Patients diagnosed with advanced HCC between 2007 and 2015 at single institute were retrospectively enrolled and evaluated for survival and tolerability following sorafenib treatment. Overall survival (OS) and duration of treatment (TTP) were examined by different stratifications including age, gender, etiology, liver functions, and severities.Results: A total of 67 advanced HCC patients were enrolled for analysis. Of the 67 eligible patients, 66 patients (99%) were diagnosed as Barcelona Clinic Liver Cancer stage C and 45 (67%) were Child-Pugh A. Chronic hepatitis B virus infection was the main etiology (67%), followed by hepatitis C virus infection (12%) and alcohol liver disease (8%). The median duration of treatment was 3.0 months (95% CI 2.6–3.4 months) and median OS was 8.0 months (95% CI 5.0–11.0 months). By multivariate analysis, female gender (HR =2.462, 95% CI 1.126–5.387, P=0.024), Child-Pugh C (HR =3.913, 95% CI 1.063–14.410, P=0.04), extrahepatic spread (HR =2.123, 95% CI 1.122–4.015, P=0.021), and combined other therapies (HR =0.410, 95% CI 0.117–0.949, P=0.037) were the independent predictors of OS.Conclusion: OS of advanced HCC patients treated with sorafenib was longer than that reported in the Asia-Pacific trial study. Impaired hepatic functions are associated with the shorter survival in real-life setting. Keywords: advanced hepatocellular carcinoma, sorafenib, liver function, tumor burden |
| first_indexed | 2024-04-13T13:49:54Z |
| format | Article |
| id | doaj.art-4f119a456a24478abdbcd2828a518493 |
| institution | Directory Open Access Journal |
| issn | 1177-8881 |
| language | English |
| last_indexed | 2024-04-13T13:49:54Z |
| publishDate | 2019-01-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Drug Design, Development and Therapy |
| spelling | doaj.art-4f119a456a24478abdbcd2828a5184932022-12-22T02:44:22ZengDove Medical PressDrug Design, Development and Therapy1177-88812019-01-01Volume 1339740443712A real-life experience of sorafenib treatment for patients with advanced hepatocellular carcinoma: a retrospective analysis at Cathay General Hospital, 2007–2015Huang CCChen HYChang RHLiao PALien HHHung CSYang SSHu JTChi-Chun Huang,1 Hsin-Yi Chen,1 Ruei-Hsin Chang,1 Pen-An Liao,2 Heng-Hui Lien,3,4 Chih-Sheng Hung,5 Sien-Sing Yang,1,3 Jui-Ting Hu1,3 1Liver Center, Cathay General Hospital Medical Center, Taipei, Taiwan; 2Department of Radiology, Cathay General Hospital Medical Center, Taipei, Taiwan; 3School of Medicine, Fu-Jen Catholic University College of Medicine, Taipei, Taiwan; 4Department of Surgery, Cathay General Hospital Medical Center, Taipei, Taiwan; 5Department of Gastroenterology, Cathay General Hospital Medical Center, Taipei, Taiwan Background: Sorafenib is an oral tyrosine kinase inhibitor that is indicated for advanced hepatocellular carcinoma (HCC). The aim of the present study was to determine the clinical outcomes of HCC patients receiving sorafenib in real-life clinical setting in comparison with formal clinical trials.Methods: Patients diagnosed with advanced HCC between 2007 and 2015 at single institute were retrospectively enrolled and evaluated for survival and tolerability following sorafenib treatment. Overall survival (OS) and duration of treatment (TTP) were examined by different stratifications including age, gender, etiology, liver functions, and severities.Results: A total of 67 advanced HCC patients were enrolled for analysis. Of the 67 eligible patients, 66 patients (99%) were diagnosed as Barcelona Clinic Liver Cancer stage C and 45 (67%) were Child-Pugh A. Chronic hepatitis B virus infection was the main etiology (67%), followed by hepatitis C virus infection (12%) and alcohol liver disease (8%). The median duration of treatment was 3.0 months (95% CI 2.6–3.4 months) and median OS was 8.0 months (95% CI 5.0–11.0 months). By multivariate analysis, female gender (HR =2.462, 95% CI 1.126–5.387, P=0.024), Child-Pugh C (HR =3.913, 95% CI 1.063–14.410, P=0.04), extrahepatic spread (HR =2.123, 95% CI 1.122–4.015, P=0.021), and combined other therapies (HR =0.410, 95% CI 0.117–0.949, P=0.037) were the independent predictors of OS.Conclusion: OS of advanced HCC patients treated with sorafenib was longer than that reported in the Asia-Pacific trial study. Impaired hepatic functions are associated with the shorter survival in real-life setting. Keywords: advanced hepatocellular carcinoma, sorafenib, liver function, tumor burdenhttps://www.dovepress.com/a-real-life-experience-of-sorafenib-treatment-for-patients-with-advanc-peer-reviewed-article-DDDTadvanced Hepatocellular carcinomaSorafenibLiver functiontumor burden |
| spellingShingle | Huang CC Chen HY Chang RH Liao PA Lien HH Hung CS Yang SS Hu JT A real-life experience of sorafenib treatment for patients with advanced hepatocellular carcinoma: a retrospective analysis at Cathay General Hospital, 2007–2015 Drug Design, Development and Therapy advanced Hepatocellular carcinoma Sorafenib Liver function tumor burden |
| title | A real-life experience of sorafenib treatment for patients with advanced hepatocellular carcinoma: a retrospective analysis at Cathay General Hospital, 2007–2015 |
| title_full | A real-life experience of sorafenib treatment for patients with advanced hepatocellular carcinoma: a retrospective analysis at Cathay General Hospital, 2007–2015 |
| title_fullStr | A real-life experience of sorafenib treatment for patients with advanced hepatocellular carcinoma: a retrospective analysis at Cathay General Hospital, 2007–2015 |
| title_full_unstemmed | A real-life experience of sorafenib treatment for patients with advanced hepatocellular carcinoma: a retrospective analysis at Cathay General Hospital, 2007–2015 |
| title_short | A real-life experience of sorafenib treatment for patients with advanced hepatocellular carcinoma: a retrospective analysis at Cathay General Hospital, 2007–2015 |
| title_sort | real life experience of sorafenib treatment for patients with advanced hepatocellular carcinoma a retrospective analysis at cathay general hospital 2007 ndash 2015 |
| topic | advanced Hepatocellular carcinoma Sorafenib Liver function tumor burden |
| url | https://www.dovepress.com/a-real-life-experience-of-sorafenib-treatment-for-patients-with-advanc-peer-reviewed-article-DDDT |
| work_keys_str_mv | AT huangcc areallifeexperienceofsorafenibtreatmentforpatientswithadvancedhepatocellularcarcinomaaretrospectiveanalysisatcathaygeneralhospital2007ndash2015 AT chenhy areallifeexperienceofsorafenibtreatmentforpatientswithadvancedhepatocellularcarcinomaaretrospectiveanalysisatcathaygeneralhospital2007ndash2015 AT changrh areallifeexperienceofsorafenibtreatmentforpatientswithadvancedhepatocellularcarcinomaaretrospectiveanalysisatcathaygeneralhospital2007ndash2015 AT liaopa areallifeexperienceofsorafenibtreatmentforpatientswithadvancedhepatocellularcarcinomaaretrospectiveanalysisatcathaygeneralhospital2007ndash2015 AT lienhh areallifeexperienceofsorafenibtreatmentforpatientswithadvancedhepatocellularcarcinomaaretrospectiveanalysisatcathaygeneralhospital2007ndash2015 AT hungcs areallifeexperienceofsorafenibtreatmentforpatientswithadvancedhepatocellularcarcinomaaretrospectiveanalysisatcathaygeneralhospital2007ndash2015 AT yangss areallifeexperienceofsorafenibtreatmentforpatientswithadvancedhepatocellularcarcinomaaretrospectiveanalysisatcathaygeneralhospital2007ndash2015 AT hujt areallifeexperienceofsorafenibtreatmentforpatientswithadvancedhepatocellularcarcinomaaretrospectiveanalysisatcathaygeneralhospital2007ndash2015 AT huangcc reallifeexperienceofsorafenibtreatmentforpatientswithadvancedhepatocellularcarcinomaaretrospectiveanalysisatcathaygeneralhospital2007ndash2015 AT chenhy reallifeexperienceofsorafenibtreatmentforpatientswithadvancedhepatocellularcarcinomaaretrospectiveanalysisatcathaygeneralhospital2007ndash2015 AT changrh reallifeexperienceofsorafenibtreatmentforpatientswithadvancedhepatocellularcarcinomaaretrospectiveanalysisatcathaygeneralhospital2007ndash2015 AT liaopa reallifeexperienceofsorafenibtreatmentforpatientswithadvancedhepatocellularcarcinomaaretrospectiveanalysisatcathaygeneralhospital2007ndash2015 AT lienhh reallifeexperienceofsorafenibtreatmentforpatientswithadvancedhepatocellularcarcinomaaretrospectiveanalysisatcathaygeneralhospital2007ndash2015 AT hungcs reallifeexperienceofsorafenibtreatmentforpatientswithadvancedhepatocellularcarcinomaaretrospectiveanalysisatcathaygeneralhospital2007ndash2015 AT yangss reallifeexperienceofsorafenibtreatmentforpatientswithadvancedhepatocellularcarcinomaaretrospectiveanalysisatcathaygeneralhospital2007ndash2015 AT hujt reallifeexperienceofsorafenibtreatmentforpatientswithadvancedhepatocellularcarcinomaaretrospectiveanalysisatcathaygeneralhospital2007ndash2015 |